Better understanding of cancer make many current cancer treatments that can work well. Chances of a full recovery or life expectancy longer increase. One of the latest treatment is promising is the target of therapy.
In targeted therapy, the treatment will be directed at cancer cells. Anti-angiogenesis therapy that has been approved by the FDA 10 years ago used as a means of cancer treatment and the results are pretty good in patients with advanced stage.
As is known, all tumors need new blood vessel growth in order to supply oxygen and nutrients that their cells can grow. Formation of new blood vessels is called angiogenesis.
"Anti-angiogenesis it will break the growth of new blood vessels so that the cancer cells die of starvation," said Dr. Ronald Hukom, Sp.PD-KHOM of Dharmais Cancer Hospital in the event Roche Health Media Forum in Jakarta, Wednesday (12.17.14).
One anti-angiogenesis cancer drug first is bevacizumab. Drugs that have been used for more than 1.5 million patients are available for breast cancer, colorectal, lung, kidney, brain, and ovary.
In Indonesia this drug has been approved by the Food and Drug Monitoring Agency (BPOM) for the indication of colorectal cancer, certain types of breast, lung and ovarian. Currently there are 14 anti-angiogenesis-based therapies approved globally, including Bevacizumab, Sorafenib, Sunitinib, Pazopanib, Regorafenib, Cabozantinib, Vandetanib, and Everolimus.
"Anti-angiogenesis has been performed in certain cancers due to other types of cancer are no results and studies are still running. We'll see hopefully a good result," said Ronald.
Ronald also add this targeted therapy should be combined with other therapies in order to maximize results. "If the result is maximum then the life expectancy of patients with advanced stage may be longer. If you had only a few months then it could be years," he said. (Eva Erviana)